昂利康(002940) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥1,380,377,636.93, representing a 7.04% increase compared to ¥1,289,647,101.26 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥119,844,202.86, a decrease of 26.80% from ¥163,719,116.52 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥107,857,508.30, down 19.51% from ¥134,000,807.56 in 2020[18]. - The company's total assets at the end of 2021 were ¥2,083,578,310.62, an increase of 7.36% from ¥1,940,754,044.72 at the end of 2020[18]. - The basic earnings per share for 2021 was ¥1.27, a decline of 29.83% compared to ¥1.81 in 2020[18]. - The weighted average return on net assets decreased to 9.13% in 2021 from 16.11% in 2020, a drop of 6.98 percentage points[18]. - The net cash flow from operating activities for 2021 was ¥197,652,364.35, a slight decrease of 0.48% from ¥198,612,986.30 in 2020[18]. - The company reported a total of ¥11,986,694.56 in non-recurring gains for 2021, down from ¥29,718,308.96 in 2020[24]. Market Expansion and Product Development - The company is actively involved in new product development and has faced challenges with the consistency evaluation of major products[4]. - The company has expanded its market presence by acquiring a controlling stake in Haixi United Pharmaceutical Co., Ltd. in August 2021[12]. - The company is focusing on expanding its product line with new drugs, although future production and sales remain uncertain for many of these products[64][65]. - The company completed the registration of three new products, including compound α-keto acid tablets and sevoflurane raw materials[41]. - The company is actively expanding into new markets, including pet pharmaceuticals and medical aesthetics, through strategic partnerships and joint ventures[43]. Research and Development - The company is focused on enhancing its R&D capabilities to innovate and develop new drugs, particularly in the field of generic drugs[4]. - R&D investment has been increased to enhance project progress and attract high-end talent, focusing on differentiated competitive products in the pharmaceutical sector[41]. - The company has several new drug projects in progress, including the approval of Ticagrelor tablets and the completion of bioequivalence studies for various products[64][65]. - The number of R&D personnel increased by 22.89% to 102 in 2021 from 83 in 2020[66]. - The company plans to increase its R&D investment to enhance its core competitiveness and accelerate the development of new products, including the "HC008" project and the expansion of alpha-keto acid raw material production[108]. Risk Management - The company acknowledges various risks including rising production costs, regulatory changes, and the impact of the ongoing pandemic on operations[4]. - The company has highlighted the need for risk awareness among investors regarding potential unlisted risks[4]. - The company acknowledges the risks associated with new product development, including potential delays and failures, and plans to implement rigorous project management to mitigate these risks[117]. - The company is prepared to address the ongoing impacts of the pandemic on its operations, ensuring that production and business activities are organized effectively[119]. - The company is actively monitoring industry regulatory changes and will adapt its internal management to comply with new standards, aiming to maintain operational stability[109]. Governance and Compliance - The company emphasizes the protection of minority shareholders' rights and has conducted shareholder meetings in compliance with legal requirements, ensuring transparency and fairness[128]. - The board of directors operates with a clear division of responsibilities and has established four specialized committees to provide professional opinions for decision-making[129]. - The company adheres to strict information disclosure practices, complying with relevant laws and regulations to maintain transparency[130]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[191]. - The company has identified no violations of national regulations or the China Securities Regulatory Commission's requirements during its governance self-inspection[177]. Environmental and Social Responsibility - The company has established wastewater treatment facilities with a design capacity of 1,000 tons per day at its headquarters and Jiangsu Yuexin, and 72 tons per day at Haixi Pharmaceutical, all operating normally[182]. - The company has implemented a robust environmental management system that meets pollution control requirements and ensures stable compliance with discharge standards[182]. - The company has achieved ISO14001 certification for its environmental management system, reflecting its commitment to environmental protection[194]. - The company has actively participated in social welfare activities, including donations of epidemic prevention materials and support for underprivileged families[195]. - The company has implemented a comprehensive review of its governance structure, financial operations, and compliance with regulatory requirements, leading to identified areas for improvement[177]. Shareholder and Financial Policies - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 93,886,819 shares[4]. - The company maintained a transparent and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[169]. - The total cash dividend, including other methods, reached RMB 91,505,097.05 for the reporting period[169]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing, with a lock-up period extending for an additional 6 months if certain conditions are met[198]. - The company must notify the stock exchange of any intended share reductions 3 trading days in advance[200].